- Home
- CBRL vs ETNB Comparison
CBRL vs ETNB Comparison
Compare CBRL & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- ETNB
- Stock Information
- Founded
- CBRL 1969
- ETNB 2018
- Country
- CBRL United States
- ETNB United States
- Employees
- CBRL N/A
- ETNB N/A
- Industry
- CBRL Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- CBRL Consumer Discretionary
- ETNB Health Care
- Exchange
- CBRL Nasdaq
- ETNB Nasdaq
- Market Cap
- CBRL 1.3B
- ETNB 1.5B
- IPO Year
- CBRL N/A
- ETNB 2019
- Fundamental
- Price
- CBRL $57.27
- ETNB $9.17
- Analyst Decision
- CBRL Hold
- ETNB Strong Buy
- Analyst Count
- CBRL 8
- ETNB 8
- Target Price
- CBRL $55.14
- ETNB $26.29
- AVG Volume (30 Days)
- CBRL 844.2K
- ETNB 1.4M
- Earning Date
- CBRL 09-18-2025
- ETNB 08-07-2025
- Dividend Yield
- CBRL 1.74%
- ETNB N/A
- EPS Growth
- CBRL N/A
- ETNB N/A
- EPS
- CBRL 2.58
- ETNB N/A
- Revenue
- CBRL $3,510,062,000.00
- ETNB N/A
- Revenue This Year
- CBRL $1.97
- ETNB N/A
- Revenue Next Year
- CBRL $1.67
- ETNB N/A
- P/E Ratio
- CBRL $22.29
- ETNB N/A
- Revenue Growth
- CBRL 2.84
- ETNB N/A
- 52 Week Low
- CBRL $33.86
- ETNB $4.16
- 52 Week High
- CBRL $71.93
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- CBRL 38.60
- ETNB 41.07
- Support Level
- CBRL $53.91
- ETNB $9.02
- Resistance Level
- CBRL $64.88
- ETNB $10.32
- Average True Range (ATR)
- CBRL 2.72
- ETNB 0.52
- MACD
- CBRL -1.19
- ETNB -0.09
- Stochastic Oscillator
- CBRL 18.65
- ETNB 34.41
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).